中文名称: | 骨化三醇 促销 | ||||
---|---|---|---|---|---|
英文名称: | 1α,25-Dihydroxyvitamin D3 | ||||
别名: | 钙三醇 1alpha,25-Dihydroxyvitamin D3;1,25-DIHYDROXYCHOLECALCIFEROL | ||||
CAS No: | 32222-06-3 | 分子式: | C27H44O3 | 分子量: | 416.64 |
CAS No: | 32222-06-3 | ||||
分子式: | C27H44O3 | ||||
分子量: | 416.64 | ||||
MDL: | MFCD00867079 | EINEC: | 250-963-8 | ||
EINEC: | 250-963-8 |
基本信息
产品编号: |
D60002 |
||||
产品名称: |
1α,25-Dihydroxyvitamin D3 |
||||
CAS: |
32222-06-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
|
|
||
分子量 |
416.64 |
|
|
||
化学名: |
1A,25-dihydroxycholecalciferol |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
83 mg/mL (199.21mM) |
|||
Ethanol |
83 mg/mL (199.21mM) |
||||
Water |
Insoluble |
||||
体内(现配现用): |
1.请依序添加每种溶剂: 10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: 2.75 mg/mL (6.60mM); Suspended solution; Need ultrasonic |
||||
此方案可获得 2.75 mg/mL (6.60mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1mL 工作液为例,取 100μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中,混合均匀;向上述体系中加入50μL Tween-80,混合均匀;然后继续加入 450μL生理盐水定容至 1mL。 |
|||||
2.请依序添加每种溶剂: 10% DMSO 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.75 mg/mL (6.60mM); Clear solution |
|||||
此方案可获得 ≥ 2.75 mg/mL (6.60mM,饱和度未知) 的澄清溶液。 以 1mL 工作液为例,取 100μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 |
|||||
3.请依序添加每种溶剂: 10% DMSO→90% corn oil Solubility: ≥ 2.75 mg/mL (6.60mM); Clear solution |
|||||
此方案可获得 ≥ 2.75 mg/mL (6.60mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1mL 工作液为例,取 100μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900μL玉米油中,混合均匀。 |
|||||
4.请依序添加每种溶剂: 5% DMSO→40% PEG300→5% Tween-80→50% saline Solubility: ≥ 2.75 mg/mL (6.60mM); Clear solution |
|||||
5.请依序添加每种溶剂: 5% DMSO→95% (20% SBE-β-CD in saline) Solubility: ≥ 2.75 mg/mL (6.60mM); Clear solution |
|||||
6.请依序添加每种溶剂: 10% EtOH→40% PEG300→5% Tween-80→45% saline Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution |
|||||
此方案可获得 ≥ 2.5 mg/mL (6.00mM,饱和度未知) 的澄清溶液。 以 1mL 工作液为例,取 100μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400μL PEG300 中,混合均匀;向上述体系中加入50μL Tween-80,混合均匀;然后继续加入 450μL生理盐水定容至 1mL。 |
|||||
7.请依序添加每种溶剂: 10% EtOH→90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.00mM); Clear solution |
|||||
此方案可获得 ≥ 2.5 mg/mL (6.00mM,饱和度未知) 的澄清溶液。 以 1mL 工作液为例,取 100μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 |
|||||
8.请依序添加每种溶剂: 10% EtOH→90% corn oil Solubility: ≥ 2.5 mg/mL (6.00mM); Clear solution |
|||||
此方案可获得 ≥ 2.5 mg/mL (6.00mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1mL 工作液为例,取 100μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900μL玉米油中,混合均匀。 |
|||||
9.请依序添加每种溶剂: 1% DMSO→99% saline Solubility: 0.55 mg/mL (1.32mM); Suspended solution; Need ultrasonic |
|||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.4002mL |
12.0008mL |
24.0015mL |
5mM |
0.4800mL |
2.4002mL |
4.8003mL |
10mM |
0.2400mL |
1.2001mL |
2.4002mL |
50mM |
0.0480mL |
0.2400mL |
0.4800mL |
生物活性
产品描述 |
一种PKC和VDR的激活剂。 |
靶点 |
vitamin D receptor |
体外研究 |
Calcitriol exerts antiproliferative effects on cervical cancer cells in vitro. Cells decrease by 12.8% when treated with 100 nM Calcitriol for 6 days, compare with control. Inhibition of cell proliferation becomes more pronounced with the increase in Calcitriol concentration. The decrease is 26.1% and 31.6% for 200 and 500nM Calcitriol, respectively. Treatment with Calcitriol for 72 h induces an evident accumulation of cells in the G1 phase, with approximately 66.18% in 200nM and 78.10% in 500nM, compare with the control (24.36%). Calcitriol treatment significantly decreases HCCR-1 protein expression compare with the control in a time- and dose-dependent manner. Calcitriol significantly increases ERα mRNA in a dose dependent manner with an EC50 of 9.8×10-9 M. |
体内研究 |
Chronic treatment with Calcitriol (150 ng/kg per day for 4.5 months) improves the relaxations (pD2: 6.30±0.09, Emax: 68.6±3.9% in Calcitriol-treated OVX, n=8). Renal blood flow in OVX rats is reduced in both kidneys, and the flow is restored by Calcitriol treatment. The increased expression of COX-2 and Thromboxane-prostanoid (TP) receptor in OVX rat renal arteries is reduced by chronic calcitriol administration. High- and low-dose Calcitriol treatment significantly decreases the systolic blood pressure (SBP) in the fructose-fed rats by 14±4 and 9±4mmHg, respectively, at Day 56. High-dose Calcitriol treatment (20ng/kg per day) significantly increases serum ionized calcium level (1.44±0.05 mmol/L) compare with the other groups. |
特征 |
|
推荐实验方法(仅供参考)
Cell Assay |
HeLa S3 cells are plated at a density of 1,000 cells/well in 96-well plates of Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), treated with 1% ethanol (control) or various concentrations of Calcitriol (100, 200, and 500nM) for 72 h. A Cell Counting Kit8 (CCK-8) is used to determine cell proliferation. At 24, 48, 72, 96, 120, and 144 h after culturing with 200nM Calcitriol, cells are harvested for analysis. Three independent experiments are performed in quadruplicate |
Animal Administration |
Adult female Sprague-Dawley rats weighing 200 to 220g are used in this study. Rats are housed in a temperature-controlled room (~23°C) with a 12-h light/dark cycle. The animals have free access to a standard diet and water. Ovariectomy (OVX) is performed on rats. At 6 months after the surgical procedure, the OVX rats are randomly assigned to either treatment with vehicle dimethyl sulfoxide (OVX+vehicle) or Calcitriol (150ng/kg daily, OVX+calcitriol). Calcitriol treatment is given by oral gavage and lasted or 4.5 months. Blood pressure and serum Calcitriol level are measured. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )